At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
XP23829 400 mg QD +3 moredrug
Likely dose
XP23829 400 mg QDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
In Brief
A Phase 2 clinical trial evaluating XP23829 400 mg QD, XP 23829 800 mg QD, and 2 other interventions for Psoriasis. Completed, enrolled 200 participants across 31 sites.
Detailed Summary
The study objectives are the following: 1. To evaluate the efficacy of 3 doses of XP23829 compared to placebo for the treatment of moderate-to-severe chronic plaque-type psoriasis. 2. To evaluate the safety and tolerability of XP23829 in subjects with psoriasis. 3. To evaluate the pharmacodynamics (PD) of XP23829 through immunological analysis of peripheral blood samples.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
CollaboratorsXenoPort, Inc.
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
First PostedJun 2014
Primary CompletionMay 2015
Study CompletionAug 2015
TodayJul 2026
First PostedJun 24, 2014
Enrollment StartJun 1, 2014
Primary CompletionMay 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.0 years ago
Interventions
XP23829 400 mg QDdrug
active dose 1
XP 23829 800 mg QDdrug
active dose 2
XP23829 400 mg BIDdrug
active dose 3
Placebodrug
control